Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
Background: Hyperuricemia is a leading risk factor for the development of chronic kidney disease (CKD). We hypothesized that lowering serum uric acid (SUA) with allopurinol in hyperuricemic children with CKD may reduce the risk of CKD progression.Methods: A total of 70 children, aged 3-15 years, wit...
| Publicado en: | Pediatric Nephrology Vol. 33; no. 8; pp. 1405 - 1410 |
|---|---|
| Autores principales: | , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Aug2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130360587&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 130360587 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0931041X EF1 jtl: Pediatric Nephrology issn: 0931041X maglogo: N pubinfo: dt: Aug2018 vid: 33 iid: 8 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 130360587 130360587 130360587 10.1007/s00467-018-3943-1 130360587 ppf: 1405 ppct: 5 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. aug: au: Ghane Sharbaf, Fatemeh Assadi, Farahnak affil: Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran sug: subj: Disease Progression Prevention and Control Renal Insufficiency, Chronic Prevention and Control Glomerular Filtration Rate Allopurinol Therapeutic Use Hyperuricemia Drug Therapy Uric Acid Blood Human Child, Preschool Child Adolescence Prospective Studies Randomized Controlled Trials Body Mass Index C-Reactive Protein Multiple Regression Blood Pressure Determination Physical Examination Treatment Outcomes Child, Preschool: 2-5 years Child: 6-12 years Adolescent: 13-18 years ab: Background: Hyperuricemia is a leading risk factor for the development of chronic kidney disease (CKD). We hypothesized that lowering serum uric acid (SUA) with allopurinol in hyperuricemic children with CKD may reduce the risk of CKD progression.Methods: A total of 70 children, aged 3-15 years, with elevated serum uric acid level (SUA) > 5.5 mg/dL and CKD stages 1-3 were prospectively randomized to receive allopurinol 5 mg/kg/day (study group, n = 38) or no treatment (control group, n = 32) for 4 months. The primary and secondary outcomes were changes in estimated glomerular filtration rate (eGFR) (> 10 mL/min/1.73m2) and the SUA (> 1.0 mg/dL) from baseline values, respectively.Results: Baseline age, gender, blood pressure (BP), body mass index (BMI), SUA, high-sensitive C-reactive protein (hsCRP), and eGFR were similar in allopurinol and control subjects. Allopurinol treatment resulted in a decrease in SUA, a decrease in systolic and diastolic BP, a decrease in hsCRP, and an increase in eGFR compared with the baseline values (p < 0.05 for all). No significant difference was observed in the control hyperuricemic subjects. In multiple regression analysis after incorporating variables (age, gender, BMI, systolic and diastolic BP, CRP, and SUA), eGFR was independently related to SUA both before and after treatments (p = 0.03 vs. p = 0.02, respectively). All patients in the study group tolerated allopurinol, and there were no adverse reactions observed by physical examination or reported by patients.Conclusion: Urate-lowering therapy with allopurinol, over a 4-month period, can improve renal function in children with CKD stages 1-3. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|